泮托拉唑、雷尼替丁治疗十二指肠溃疡药物经济学对比研究

顾永红

（绥德县医院药剂科，陕西 榆林，718000）

浏览次数：161次 下载次数：459次

摘要：

目的 对比泮托拉唑、雷尼替丁治疗十二指肠溃疡的药物经济学差异。方法 选取本院84例十二指肠溃疡的患者，随机分成试验组和对照组，各42例。对照组患者采用雷尼替丁进行治疗，而试验组患者采用泮托拉唑进行治疗，并同时对两组患者进行保护胃黏膜及抗Hp等常规治疗，观察对比两组患者的治疗效果并进行药物经济学效果比较。结果 试验组患者的治疗总有效率为97.62%，明显高于对照组的83.33%（P<0.05）；试验组出现2例轻度腹泻，对照组出现1例便秘和1例皮疹，两组不良反应发生率均为4.76%，两组不良反应发生率无显著差异（P<0.05）；试验组的C/E比值为183.88，高于对照组的 97.68。结论 在治疗十二指肠溃疡患者时，泮托拉唑的治疗效果要优于雷尼替丁，但雷尼替丁的药物经济学效果要优于泮托拉唑，因此在临床上选择药物时需要根据患者的实际情况，选择合适的治疗药物。

关键词：泮托拉唑；雷尼替丁；十二指肠溃疡；药物经济学

中图分类号：R573文献标志码：A文章编号：2096-1413(2017)20-0035-02

Pharmacoeconomics comparative study of pantoprazole and ranitidine in the treatment of duodenal ulcer
GU Yong-hong
(Department of Pharmacy, Suide County Hospital, Yulin 718000, China)

ABSTRACT: Objective To compare the pharmacoeconomics between pantoprazole and ranitidine in the treatment of duodenal ulcer. Methods Eighty four cases of patients with duodenal ulcer in our hospital were randomly divided into experimental group and control group, with 42 cases in each group. The patients in the control group were treated with ranitidine, and the patients in the experimental group were treated with pantoprazole. Both groups were treated with routine treatment such as gastric mucosa and anti -Hp. The therapeutic effects and pharmacoeconomics in the two groups were observed. Results The total effective rate in the experimental group was 97.62%, which was significantly higher than 83.33% in the control group (P<0.05). There were 2 cases of mild diarrhea in the experimental group, 1 case of constipation and 1 case of rash in the control group, the incidence of adverse reactions was 4.76% in the two groups, there was no significant difference in the incidence of adverse reactions between the two groups (P<0.05); the C/E ratio of the experimental group was 183.88, which was higher than 97.68 of the control group. Conclusion The clinical efficacy of transotrazole is superior to that of ranitidine in the treatment duodenal ulcer, but the pharmacoeconomics of ranitidine is better than the pantoprazole. Therefore, appropriate treatment should be selected in clinic on the basis of the patients`` actual situation.
KEYWORDS: pantoprazole; ranitidine; duodenal ulcer; pharmacoeconomics

参考文献：
[1] 张家兴,谢娟,高玲,等.泮托拉唑与雷尼替丁治疗胃食管反流的药物经济学评价[J].中国药房,2016,27(29):4037-4041.
[2] 纪晓霞.3 种质子泵抑制剂治疗Hp 阳性十二指肠溃疡的疗效比较[J].实用临床医药杂志,2013,17(24):116-117.
[3] 张征.不同剂量质子泵抑制剂三联疗法治疗幽门螺杆菌阳性十二指肠溃疡的疗效评价[J].中华临床医师杂志:电子版,2012,6(22):7426-7427.
[4] 申利敏.兰索拉唑预防长期非类固醇抗炎药相关胃和十二指肠溃疡的效果观察[J].现代消化及介入诊疗,2015,20(6):649-651.
[5] 刘铎,孙明军,魏敏杰.泮托拉唑治疗十二指肠溃疡的系统评价[J].中国医院药学杂志,2012,32(2):141-144.
[6] 管卓淼.泮托拉唑治疗十二指肠溃疡的临床疗效分析[J].求医问药:学术版,2012,10(2):411.
[7] 孙建枢.3 种质子泵抑制剂治疗十二指肠溃疡药物经济学分析[J].海峡药学,2011,23(8):190-191.
[8] 张红新,田晓娟,张轲.泮托拉唑与雷尼替丁联合抗生素治疗胃溃疡的疗效比较[J].临床医学,2014,34(7):54-55.
[9] 王红彬.质子泵抑制剂(拉唑类)药物与雷尼替丁对十二指肠球部溃疡治疗效果比较[J].中国实用医药,2012,7(35):158-159.
[10] 金振亮.泮托拉唑与雷尼替丁分别联合抗生素治疗胃溃疡的疗效比较[J].临床合理用药杂志,2015,8(10):60-61.
[11] 张艳玲,贾立英,徐辉,等.含呋喃唑酮的三联疗法治疗儿童幽门螺杆菌感染[C]//中华医学会第十四次全国儿科学术会议论文汇编.2006:52-54.